Published in Anticancer Agents Med Chem on February 01, 2010
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev (2010) 1.33
New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today (2010) 0.99
Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev (2013) 0.89
Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013) 0.85
Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. Brain Pathol (2011) 0.82
Chemoquiescence for ideal cancer treatment and prevention: where are we now? J Cancer Prev (2014) 0.81
High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde. Mol Cancer (2011) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Melanoma biology and new targeted therapy. Nature (2007) 10.71
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer (2005) 9.04
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Identification of cells initiating human melanomas. Nature (2008) 8.28
Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res (2008) 7.65
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A (2004) 6.84
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Tissue repair and stem cell renewal in carcinogenesis. Nature (2004) 6.28
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol (2007) 5.80
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res (2007) 5.32
Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5.30
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol (2006) 5.17
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol (2004) 5.10
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer (2002) 5.02
Telomeres and aging. Physiol Rev (2008) 4.79
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci (2007) 4.07
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One (2008) 3.97
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res (2005) 3.79
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 3.76
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells (2005) 3.66
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 3.60
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol (2004) 3.41
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A (2008) 3.13
Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev (2006) 3.09
Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res (2007) 3.00
Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One (2008) 2.90
Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72
Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol (2007) 2.70
Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res (2007) 2.68
Current indications for chemotherapy in prostate cancer patients. Eur Urol (2006) 2.68
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Cancer stem cells in radiation resistance. Cancer Res (2007) 2.59
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol (2005) 2.43
A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol (2007) 2.43
Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem (2008) 2.42
In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst (2009) 2.39
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res (2007) 2.34
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer (2009) 2.33
Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer (2004) 2.32
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 2.28
ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest (2009) 2.25
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas (2005) 2.23
Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res (2007) 2.22
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 2.21
Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol (2004) 2.19
Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther (2007) 2.19
Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res (2006) 2.18
The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A (2007) 2.18
Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol (2008) 2.18
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res (2009) 2.14
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res (2009) 2.09
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res (2006) 2.02
Identification of local and circulating cancer stem cells in human liver cancer. Hepatology (2008) 2.02
The human PAF complex coordinates transcription with events downstream of RNA synthesis. Genes Dev (2005) 2.70
Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res (2004) 2.66
Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am J Gastroenterol (2006) 2.51
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas (2005) 2.23
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate (2002) 2.05
MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res (2007) 2.00
Breast cancer survival of Hispanic women in the USA is influenced by country of origin. Asia Pac J Clin Oncol (2013) 1.99
Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.85
Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol (2010) 1.81
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res (2008) 1.77
Structure, evolution, and biology of the MUC4 mucin. FASEB J (2007) 1.75
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett (2013) 1.74
Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol (2010) 1.65
Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta (2006) 1.65
Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res (2007) 1.61
Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2004) 1.59
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol (2013) 1.58
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol (2006) 1.55
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis (2005) 1.55
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006) 1.50
MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am J Gastroenterol (2006) 1.48
MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res (2006) 1.46
Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One (2011) 1.43
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells (2006) 1.40
Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate (2006) 1.40
Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol (2006) 1.39
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev (2008) 1.36
Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev (2010) 1.33
Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci (2009) 1.31
Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas (2003) 1.30
Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis (2002) 1.27
Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One (2011) 1.26
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer (2006) 1.26
Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med (2012) 1.23
Neural invasion in the staging of pancreatic cancer. Pancreas (2003) 1.23
MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer (2006) 1.22
Engineering antibodies for clinical applications. Trends Biotechnol (2007) 1.21
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett (2007) 1.20
Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta (2011) 1.20
Current status of mucins in the diagnosis and therapy of cancer. Biofactors (2009) 1.17
Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol (2013) 1.17
Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate (2007) 1.17
Recent trends in antibody-based oncologic imaging. Cancer Lett (2011) 1.17
Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther (2010) 1.16
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther (2007) 1.15
Marital status and survival in pancreatic cancer patients: a SEER based analysis. PLoS One (2011) 1.14
MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res (2008) 1.13
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol (2003) 1.13
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
What is the origin of pancreatic adenocarcinoma? Mol Cancer (2003) 1.11
Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol (2008) 1.11
Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res (2006) 1.10
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res (2004) 1.10
Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 1.10
MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS One (2012) 1.09
Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res (2008) 1.08
MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett (2010) 1.08
Taurocholate-induced pancreatitis: a model of severe necrotizing pancreatitis in mice. Pancreas (2008) 1.07
Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One (2012) 1.06
Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J Hematol Oncol (2012) 1.06
Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett (2012) 1.06
RNA polymerase II associated factor 1/PD2 maintains self-renewal by its interaction with Oct3/4 in mouse embryonic stem cells. Stem Cells (2009) 1.05
High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer (2010) 1.05
Characterization of human mucin MUC17. Complete coding sequence and organization. J Biol Chem (2006) 1.04
Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. Anal Chem (2011) 1.03
Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res (2005) 1.03
Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J Biol Chem (2010) 1.03
A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol (2007) 1.03
Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med (2011) 1.03
Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res (2010) 1.03
Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev (2008) 1.02
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther (2010) 1.01
Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon. J Clin Pathol (2010) 1.01
MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett (2009) 1.01
Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PLoS One (2013) 1.01
A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene (2004) 1.00
Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des (2012) 1.00
Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol (2004) 1.00
Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer (2003) 0.99
New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today (2010) 0.99
MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis (2012) 0.99
Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology (2012) 0.98
Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int J Cancer (2009) 0.98
Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett (2007) 0.97
Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene (2005) 0.97
Genomic organization of MUC4 mucin gene. Towards the characterization of splice variants. Eur J Biochem (2002) 0.95
Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem Biophys Res Commun (2003) 0.95
Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev (2007) 0.95
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol (2012) 0.94
Pancreatic enzyme extract improves survival in murine pancreatic cancer. Pancreas (2004) 0.94
Characterization of nonmalignant and malignant prostatic stem/progenitor cells by Hoechst side population method. Methods Mol Biol (2009) 0.94
The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. PLoS One (2009) 0.94
Cigarette smoke-induced pancreatic damage: experimental data. Langenbecks Arch Surg (2008) 0.93
Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res (2007) 0.92
MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer (2011) 0.92